©bongkarn thanyakij via Canva.com
Better Understand the Activity of Oncology Drugs by Combining the Power of Different Profiling Approaches
This Webinar is over| Date | Apr 26, 2017 |
| Time | 10:00 AM EDT |
| Cost | Free |
|
Online
|
Profiling the properties of agents for eventual therapeutic utility is an essential part of drug discovery and development. Evaluating the in vitro potency of kinase or epigenetic inhibitors in a wide panel of enzyme assays is critical, not only to guiding SAR knowledge for improving drug design, but also for evaluating selectivity, which has important consequences for both biological activity and safety. Evaluation of the same inhibitors in cellular models yields information on the activity of these inhibitors in a more physiologically relevant environment. Using both enzymatic and cellular assays helps to define how an inhibitor works, the signaling networks affected by it, and its ultimate therapeutic application.
In our webinar, we will demonstrate the power of evaluating several well-known kinase and epigenetic inhibitors in complementary profiling panel assays to better predict behavior that has implications for clinical activity. Our examples will highlight the need to not only understand an inhibitor’s fundamental activity(ies) at its designated target(s), but also its cellular context, when assessing the maximum potential clinical utility. With careful evaluation of the in vitro enzyme activity profiles of inhibitors using KinaseProfiler™, along with cellular response profiles and genomic biomarker identification using the OncoPanel™ Cell-Based Profiling Service, a more complete picture of their biological activity can be generated. This kind of comprehensive analysis also opens up the possibility for expanding the clinical utility of an existing target, or therapeutic asset, by potential repurposing for other indications.
Learning Objectives:
Understand the value of both enzymatic and cellular analyses to obtain the most physiologically relevant data for oncology therapeutics in drug discovery
Navigate the potential impact of both on-target and off-target activities for oncology therapeutics in a cellular context
Appreciate how comprehensive enzymatic and cellular data can provide information on the potential repurposing of therapeutics for other indications
Who Should Attend:
Research Scientist, Senior Scientist, R&D Scientist, Drug Discovery Scientist, Oncology Drug Discovery Scientist
Speaker:
Alastair J. King, Ph.D., Principal Scientist, OncoPanel Group Leader, Eurofins Pharma Discovery Services
In our webinar, we will demonstrate the power of evaluating several well-known kinase and epigenetic inhibitors in complementary profiling panel assays to better predict behavior that has implications for clinical activity. Our examples will highlight the need to not only understand an inhibitor’s fundamental activity(ies) at its designated target(s), but also its cellular context, when assessing the maximum potential clinical utility. With careful evaluation of the in vitro enzyme activity profiles of inhibitors using KinaseProfiler™, along with cellular response profiles and genomic biomarker identification using the OncoPanel™ Cell-Based Profiling Service, a more complete picture of their biological activity can be generated. This kind of comprehensive analysis also opens up the possibility for expanding the clinical utility of an existing target, or therapeutic asset, by potential repurposing for other indications.
Learning Objectives:
Understand the value of both enzymatic and cellular analyses to obtain the most physiologically relevant data for oncology therapeutics in drug discovery
Navigate the potential impact of both on-target and off-target activities for oncology therapeutics in a cellular context
Appreciate how comprehensive enzymatic and cellular data can provide information on the potential repurposing of therapeutics for other indications
Who Should Attend:
Research Scientist, Senior Scientist, R&D Scientist, Drug Discovery Scientist, Oncology Drug Discovery Scientist
Speaker:
Alastair J. King, Ph.D., Principal Scientist, OncoPanel Group Leader, Eurofins Pharma Discovery Services
Create your own event
Turn your passion into a business.
Turn your passion into a business.